Cogent Biosciences Net Income 2016-2021 | COGT

Cogent Biosciences net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cogent Biosciences Annual Net Income
(Millions of US $)
2020 $-179
2019 $-32
2018 $-35
2017 $-26
2016 $-18
2015 $-7
Cogent Biosciences Quarterly Net Income
(Millions of US $)
2021-06-30 $-17
2021-03-31 $-12
2020-12-31 $-116
2020-09-30 $-50
2020-06-30 $-7
2020-03-31 $-6
2019-12-31 $2
2019-09-30 $-12
2019-06-30 $-11
2019-03-31 $-12
2018-12-31 $-9
2018-09-30 $-10
2018-06-30 $-9
2018-03-31 $-7
2017-12-31 $-7
2017-09-30 $-7
2017-06-30 $-6
2017-03-31 $-6
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.326B $0.008B
Cogent Biosciences Inc. is a biotechnology company. It is focused on developing precision therapies for genetically defined diseases. The company's program consist PLX9486. Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc., is based in CAMBRIDGE, Mass.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76